HUE055155T2 - Módszerek a tónusos gátlás növelésére és a másodlagos álmatlanság kezelésére - Google Patents

Módszerek a tónusos gátlás növelésére és a másodlagos álmatlanság kezelésére

Info

Publication number
HUE055155T2
HUE055155T2 HUE15803364A HUE15803364A HUE055155T2 HU E055155 T2 HUE055155 T2 HU E055155T2 HU E15803364 A HUE15803364 A HU E15803364A HU E15803364 A HUE15803364 A HU E15803364A HU E055155 T2 HUE055155 T2 HU E055155T2
Authority
HU
Hungary
Prior art keywords
methods
treating secondary
tonic inhibition
secondary insomnia
increasing tonic
Prior art date
Application number
HUE15803364A
Other languages
English (en)
Hungarian (hu)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of HUE055155T2 publication Critical patent/HUE055155T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
HUE15803364A 2014-06-06 2015-06-03 Módszerek a tónusos gátlás növelésére és a másodlagos álmatlanság kezelésére HUE055155T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462008939P 2014-06-06 2014-06-06

Publications (1)

Publication Number Publication Date
HUE055155T2 true HUE055155T2 (hu) 2021-11-29

Family

ID=54767324

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE15803364A HUE055155T2 (hu) 2014-06-06 2015-06-03 Módszerek a tónusos gátlás növelésére és a másodlagos álmatlanság kezelésére
HUE18169211A HUE055400T2 (hu) 2014-06-06 2015-06-03 Módszerek a tónusos gátlás növelésére és az Angelman-szindróma kezelésére

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE18169211A HUE055400T2 (hu) 2014-06-06 2015-06-03 Módszerek a tónusos gátlás növelésére és az Angelman-szindróma kezelésére

Country Status (20)

Country Link
US (11) US20150352085A1 (https=)
EP (3) EP3151832B1 (https=)
JP (4) JP2017516868A (https=)
AR (1) AR100772A1 (https=)
AU (4) AU2015269667B2 (https=)
CA (1) CA2950845C (https=)
CY (2) CY1124368T1 (https=)
DK (2) DK3151832T3 (https=)
ES (2) ES2875742T3 (https=)
HR (2) HRP20210901T1 (https=)
HU (2) HUE055155T2 (https=)
IL (2) IL249287B (https=)
LT (2) LT3372229T (https=)
MX (2) MX380868B (https=)
PL (2) PL3372229T3 (https=)
PT (2) PT3151832T (https=)
RS (2) RS62006B1 (https=)
SI (2) SI3372229T1 (https=)
SM (2) SMT202100343T1 (https=)
WO (1) WO2015187851A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3065782B8 (en) 2013-11-05 2021-05-26 Elena Molokanova Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels
DK3151832T3 (da) 2014-06-06 2021-06-14 Ovid Therapeutics Inc Fremgangsmåder til øgning af tonisk hæmning og behandling af sekundær søvnløshed
US10434308B2 (en) 2015-05-29 2019-10-08 Medtronic, Inc. Impedance matching and electrode conditioning in patient interface systems
US10080898B2 (en) * 2015-05-29 2018-09-25 Medtronic, Inc. Simultaneous physiological sensing and stimulation with saturation detection
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
IL256912B2 (en) * 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods of treating developmental disorders with gaboxadol
WO2018017639A1 (en) * 2016-07-19 2018-01-25 Georgia State University Research Foundation Methods for treating rett syndrome
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
EP3528807A4 (en) * 2016-11-22 2020-06-17 Ovid Therapeutics Inc METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
JP2020529440A (ja) 2017-08-04 2020-10-08 オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics Inc. 糖尿病および関連する状態の処置におけるガボキサドールの使用
US11181384B2 (en) * 2018-07-23 2021-11-23 Waymo Llc Verifying map data using challenge questions
MX2021003302A (es) 2018-09-20 2021-05-13 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.
US11123332B2 (en) * 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
EP3880201A4 (en) 2018-12-17 2022-07-27 Ovid Therapeutics Inc. USE OF GABOXADOL IN THE TREATMENT OF NON-24 HOUR SLEEP waking disorder
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
KR20220035195A (ko) * 2019-07-15 2022-03-21 오비드 테라퓨틱스 인크. 치료적 치료를 위한 가복사돌을 포함하는 약학적 제제
EP4051272A4 (en) 2019-12-18 2023-01-04 Ovid Therapeutics Inc. GABOXADOL FOR THE THERAPEUTIC TREATMENT OF 1P36 DELETION SYNDROME
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
JP7600661B2 (ja) * 2020-12-11 2024-12-17 artience株式会社 貼付剤
US20240285562A1 (en) * 2023-02-17 2024-08-29 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
JP2007530604A (ja) 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
DE102005020882A1 (de) * 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
CA2705733C (en) 2007-11-13 2015-02-03 Cadence Pharmaceuticals Reduced dose intravenous acetaminophen
CN102137667A (zh) * 2008-09-01 2011-07-27 H.隆德贝克有限公司 包含加波沙朵和patl或oat抑制剂的药物组合物
DK3151832T3 (da) 2014-06-06 2021-06-14 Ovid Therapeutics Inc Fremgangsmåder til øgning af tonisk hæmning og behandling af sekundær søvnløshed
IL256912B2 (en) * 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods of treating developmental disorders with gaboxadol
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Also Published As

Publication number Publication date
RS62007B1 (sr) 2021-07-30
DK3151832T3 (da) 2021-06-14
EP3151832A1 (en) 2017-04-12
ES2875742T3 (es) 2021-11-11
JP2023123442A (ja) 2023-09-05
MX391502B (es) 2025-03-21
SMT202100340T1 (it) 2021-07-12
US20150352085A1 (en) 2015-12-10
US9744159B2 (en) 2017-08-29
JP2021178836A (ja) 2021-11-18
PL3372229T3 (pl) 2021-10-04
AU2020217342A1 (en) 2020-08-27
PT3151832T (pt) 2021-06-15
US20160038469A1 (en) 2016-02-11
US20160228418A1 (en) 2016-08-11
CY1124368T1 (el) 2022-07-22
US20170273956A1 (en) 2017-09-28
HRP20210901T1 (hr) 2021-09-17
RS62006B1 (sr) 2021-07-30
JP2017516868A (ja) 2017-06-22
US11278529B2 (en) 2022-03-22
CA2950845C (en) 2023-04-25
US9446028B2 (en) 2016-09-20
IL268960B (en) 2021-05-31
US20170087133A1 (en) 2017-03-30
EP3372229B1 (en) 2021-03-24
AU2022200085A1 (en) 2022-02-03
MX380868B (es) 2025-03-12
AU2024202604A1 (en) 2024-05-09
EP3372229A1 (en) 2018-09-12
DK3372229T3 (da) 2021-06-14
HRP20210902T1 (hr) 2021-09-17
SI3151832T1 (sl) 2021-08-31
CY1124366T1 (el) 2022-07-22
US20180303805A1 (en) 2018-10-25
SI3372229T1 (sl) 2021-09-30
IL268960A (en) 2019-10-31
PT3372229T (pt) 2021-06-17
AU2015269667A1 (en) 2016-12-22
MX2016016136A (es) 2017-07-05
WO2015187851A1 (en) 2015-12-10
IL249287A0 (en) 2017-02-28
US9801864B2 (en) 2017-10-31
LT3151832T (lt) 2021-07-12
EP3795156A1 (en) 2021-03-24
US20220016091A1 (en) 2022-01-20
US20250025448A1 (en) 2025-01-23
IL249287B (en) 2021-03-25
AU2020217342B2 (en) 2021-10-07
SMT202100343T1 (it) 2021-07-12
US20230051859A1 (en) 2023-02-16
US20170071917A1 (en) 2017-03-16
JP2020063264A (ja) 2020-04-23
MX2020012404A (es) 2022-04-11
ES2876350T3 (es) 2021-11-12
CA2950845A1 (en) 2015-12-10
AU2015269667B2 (en) 2020-07-30
US9339495B2 (en) 2016-05-17
PL3151832T3 (pl) 2021-10-25
HUE055400T2 (hu) 2021-11-29
EP3151832A4 (en) 2018-01-17
LT3372229T (lt) 2021-07-12
US20180015076A1 (en) 2018-01-18
AR100772A1 (es) 2016-11-02
EP3151832B1 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
HUE055155T2 (hu) Módszerek a tónusos gátlás növelésére és a másodlagos álmatlanság kezelésére
HUS2500046I1 (hu) BTK-inhibitor és BCL-2-inhibitor terápiás kombinációi
IL266458A (en) Equipment and methods for treating objects
HUE052104T2 (hu) Eszközök és eljárások HBV kezelésére
HUE053485T2 (hu) Készítmények és eljárások meibom-mirigy diszfunkció kezelésére
HUE066468T2 (hu) Idegnyugtató norketamin vegyületek és eljárások
SG11201607031SA (en) Verification methods and verification devices
IL251759B (en) Compositions and methods for treating insomnia
PT3197403T (pt) Planeamento cirúrgico e método
IL253234A0 (en) Methods for transdifferentiation and methods to use them
SG11201700675UA (en) Implant masking and alignment
SG10201913641XA (en) Viral Prophylaxis Treatment Methods and Pre-Exposure Prophylaxis Kits
DE102015100109A8 (de) Lithiumionensekundärbatterie und verfahren des herstellens derselben
IL256109A (en) Methods for the treatment or prevention of protopathy
IL256181A (en) Means and methods for treatment of b-cell malignancies
IL252904A0 (en) Methods and factors for treating diseases
PL3180295T3 (pl) Sposób szybkiej humifikacji i biostabilizacji
IL251162A0 (en) Monoamine oxidase-B inhibitors and rehabilitation
IL248035A0 (en) Database and the method of using it
GB2527908B (en) Closure means and method of use thereof
GB201806609D0 (en) A method of treatment and prognosis
IL248185A0 (en) Kit and method to create a brace
PL3198041T3 (pl) Układ króćca dostępowego i sposób jego wytwarzania
GB201416883D0 (en) Surgical planning and method
GB201416797D0 (en) Contianer and method of use thereof